Report Highlights

U.S. PD-L1 Inhibitors: Market Overview

The U.S. PD-L1 inhibitor market was valued at USD 6.9 billion in 2024 and is anchored by three FDA-approved agents: atezolizumab (Tecentriq, Genentech), durvalumab (Imfinzi, AstraZeneca) and avelumab (Bavencio, Merck KGaA and Pfizer). Cosibelimab (Unloxcyt, Checkpoint Therapeutics) received FDA approval in December 2024 for cutaneous squamous cell carcinoma. Private sector firms have driven clinical development, while the government's role is confined to regulatory gatekeeping and public payment through Medicare.

Government influence concentrates in two channels: regulatory approval by the FDA under the Federal Food, Drug, and Cosmetic Act, and public payment through Medicare Part B, where Section 1847A of the Social Security Act pays biologics at average sales price plus 6 percent. Section 340B of the Public Health Service Act adds a discounted purchasing channel for safety-net hospitals, reshaping where drugs are dispensed. Net effect: market structure reflects federal payment formulas as much as clinical evidence.

Policy-Driven Growth in U.S. PD-L1 Inhibitors

The Inflation Reduction Act of 2022 (Public Law 117-169) reshapes patient demand through Part B inflation rebates administered by CMS, which reduce beneficiary coinsurance on drugs whose prices rise faster than the inflation benchmark. This lowers out-of-pocket exposure for Medicare patients receiving atezolizumab or durvalumab, sustaining infusion volume in community oncology settings. Separately, the Medicare Drug Price Negotiation Program under the same Act sets negotiated maximum fair prices for selected Part B drugs from 2028, a constraint on net revenue that shifts growth toward volume.

CMS's Enhancing Oncology Model, launched in July 2022 under the Center for Medicare and Medicaid Innovation, pays participating practices $160 per beneficiary per month to manage chemotherapy-related toxicity, favoring immunotherapy regimens that carry lower hospitalization risk in first-line disease. FDA's Project Orbis, coordinated by the Oncology Center of Excellence, runs concurrent reviews with Australia, Canada, Brazil, Israel, Singapore, Switzerland and the United Kingdom, accelerating global launches of durvalumab-based labels. Together these programs convert clinical value into faster and broader reimbursed uptake.

Regulatory Barriers and Compliance Costs in the U.S. Market

Biologics are licensed under Section 351 of the Public Health Service Act, with FDA's Center for Drug Evaluation and Research reviewing each Biologics License Application against PDUFA VII goals of ten months for standard review and six months for priority review. Under the Food and Drug Omnibus Reform Act of 2022 (Division FF of Public Law 117-328), accelerated approval now requires sponsors to begin confirmatory trials before granting the approval, a pre-approval obligation that raises development spend and delays launch timing.

Each PD-L1 label requires a companion diagnostic, regulated as a medical device by FDA's Center for Devices and Radiological Health through premarket approval, so validated immunohistochemistry assays such as VENTANA SP142 and SP263 must run in CLIA-certified laboratories under CMS oversight. Coverage adds friction: Medicare contractors issue local coverage determinations for testing, and the Part B inflation rebate adjusts coinsurance quarterly, compressing infusion-site margins.

Policy-Created Opportunities for U.S. PD-L1 Inhibitors

Biomarker-defined labeling creates a diagnostic procurement channel. Because FDA's Center for Devices and Radiological Health approves companion diagnostics alongside each PD-L1 label, CLIA-certified laboratories with validated VENTANA or equivalent immunohistochemistry capability can capture testing volume generated by every label restricting use to tumors with defined expression thresholds, such as the 1% cutoff in atezolizumab's first-line lung indication.

The Enhancing Oncology Model offers a second opening for data services. Participating practices must report quality and utilization data to CMS and earn the $160 per beneficiary per month payment only while meeting performance standards, which creates demand for real-world evidence platforms and toxicity-tracking software among community oncology groups. Project Orbis-linked launches also open demand for regional regulatory filing support in Australia, Canada and Brazil.

Market at a Glance

Leading Market Participants

• Hoffmann-La Roche
• Genentech
• AstraZeneca
• Merck KGaA
• Pfizer
• Checkpoint Therapeutics
• Sun Pharmaceutical Industries
• Roche Diagnostics
• Agilent Technologies
• Cencora

Regulatory and Policy Environment for U.S. PD-L1 Inhibitors

The primary legislation is the Federal Food, Drug, and Cosmetic Act, supplemented by Section 351 of the Public Health Service Act for biologics, with FDA's Center for Drug Evaluation and Research administering licensure. Key compliance requirements include postmarketing safety reporting under 21 CFR 600.80, confirmatory trial obligations under the Food and Drug Omnibus Reform Act of 2022, and Open Payments disclosure of manufacturer payments to prescribers under Section 6002 of the Affordable Care Act. Pricing is governed by the Inflation Reduction Act of 2022 (Public Law 117-169).

Upcoming changes are concrete: CMS will publish negotiated maximum fair prices for the third negotiation cycle, including the first Part B drugs, for initial price applicability year 2028 by 30 November 2026. Atezolizumab's 12-year reference product exclusivity under Section 351(k)(7) of the Public Health Service Act expires in May 2028, opening biosimilar filings. Compared with regional peers, the EU's Regulation (EU) 2021/2282 applied joint clinical assessments to oncology medicines from 12 January 2025, centralizing evidence review in a way the U.S. lacks, where no federal health technology assessment body exists.

Long-Term Policy Outlook for U.S. PD-L1 Inhibitors

By 2032, the dominant policy force will be Medicare price negotiation layered over biosimilar entry. Atezolizumab faces biosimilar competition from 2028, while durvalumab and avelumab reach reference exclusivity expiry in 2029 under the same 12-year provision. Negotiated prices will reset Medicare Part B reimbursement baselines, pushing originators toward subcutaneous formulations such as Tecentriq Hybreza, approved in September 2024, and broader label expansion to protect volume.

Executive Order 14297 of 12 May 2025 on most-favored-nation drug pricing directs federal agencies to benchmark Medicare and Medicaid prices against lower-priced foreign markets, a policy whose implementation will shape reimbursement negotiations with originators through 2032. Continued Part B inflation rebates will operate alongside EOM participation. Reform trajectories favor volume growth at lower unit prices, with originators absorbing margin compression as biosimilar entry arrives.